title: Successful management of sudden, massive immune hemolysis following ABO-incompatible allogeneic PBSCT despite methotrexate GvHD prophylaxis.
authors.forename: D M
authors.initials: DM
authors.lastname: Benson
authors.forename: L
authors.initials: L
authors.lastname: O'Donnell
authors.forename: D
authors.initials: D
authors.lastname: Krugh
authors.forename: T
authors.initials: T
authors.lastname: Grady
authors.forename: W
authors.initials: W
authors.lastname: Blum
authors.forename: J D
authors.initials: JD
authors.lastname: Williams
authors.forename: M S
authors.initials: MS
authors.lastname: Kennedy
authors.forename: G
authors.initials: G
authors.lastname: Marcucci
mesh_terms: D000017:ABO Blood-Group System; D000328:Adult; D001402:B-Lymphocytes / Q000378:metabolism; D001549:Benzamides; D001787:Blood Group Incompatibility; D006086:Graft vs Host Disease / Q000628:therapy*; D006461:Hemolysis / Q000276:immunology*; D006801:Humans; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008297:Male; D008727:Methotrexate / Q000494:pharmacology*; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D013997:Time Factors; D014184:Transplantation, Homologous / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D000017:ABO Blood-Group System; D001549:Benzamides; D007166:Immunosuppressive Agents; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D008727:Methotrexate